Navigation Links
Start of Phase II Study for Intranasal, Seasonal Influenza Vaccine deltaFLU
Date:1/13/2010

VIENNA, Austria, January 13 /PRNewswire/ --

- By Starting the Phase II Study for deltaFLU, AVIR Green Hills AG has Accomplished yet Another Milestone in the Development of this Novel Influenza Vaccine. Completion of this Clinical Phase II Study is Envisaged for Spring 2010

- The Positive Results Obtained in the Previous Clinical Phase I Study will be Published in the Renowned "Journal of Infectious Diseases" on 15 January 2010

AVIR Green Hills Biotechnology, the innovative biotech company based in Vienna, has started the New Year by embarking on the first clinical phase II study for the seasonal vaccine deltaFLU. The study will be carried out at the Medical University of Vienna. With this step, AVIR Green Hills has set yet another important milestone in the development of effective and modern influenza vaccines.

Start of clinical phase II study

In a randomized double blind study, the vaccine will be administered intranasally to 48 volunteers.

"In double blind studies, neither the administering physician (and/or the commissioning party) nor the volunteers know who gets the placebo. Moreover, none of them knows which sprays contain the tested vaccine and which contain the placebo," explains Franz Groiss, who is in charge of managing clinical studies at AVIR Green Hills Biotechnology. The study will be headed by Volker Wacheck and carried out at the Department of Clinical Pharmacology at the Vienna General Hospital.

Aim of phase II study

The aim of the phase II study is to optimize the vaccine dose and to substantiate the efficiency of the vaccine and its ability to trigger an immune response.


'/>"/>

SOURCE AVIR Green Hills Biotechnology AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
2. JumpStart Invests in Checkpoint Surgical
3. Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity
4. Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
5. Dong-A PharmTech Co., Ltd. Announces Start of Phase III Trials for Udenafil, Its New Erectile Dysfunction Drug Under Development
6. AMT Starts Development LPLChip(TM) With Progenika
7. American Association for Homecare Proposes Strong Anti-Fraud Measures in Medicare, Applauds HHS Testimony Today That Pledges to "Stop Fraud Before it Starts"
8. Patients who Participated in Pleio GoodStart(TM) Refilled 30% Sooner and 40% More, Averaging 2 Additional Rx Refills per Patient
9. R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
10. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial
11. Cytopias CYT387 Receives FDA Clearance to Start US Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014 The ... physicians is spreading to previously rep-friendly specialties, according ... sales and marketing consulting firm ZS Associates.      ... than 200 U.S. pharmaceutical sales teams. The report ... prescribers meet with the pharmaceutical sales reps who ...
(Date:7/22/2014)... July 22, 2014  Pressure BioSciences, Inc. ... Parabase Genomics ("Parabase"), (together "the companies"), today ... research and development agreement (the "collaboration"). Under ... develop a front-end, sample preparation method for ... confirmatory testing process. The sample preparation method ...
(Date:7/22/2014)... 2014 Glide ... on solid dose formulations of therapeutics and vaccines, ... octreotide acetate achieved successful results in a pre-clinical ... liquid product (Sandostatin®).  Based on these results, the ... to a contract manufacturing organisation (CMO), and to ...
Breaking Medicine Technology:Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 2Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 3Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 4Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 5Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide 2
... Corp. (NYSE: CFN ), a leading, global medical ... Sept. 30, 2010. "Our adjusted EPS results for ... highlighted a strong quarter for our Infusion, Dispensing, Infection Prevention ... of CareFusion. "In the first quarter we essentially overcame $60 ...
... 2, 2010 Elekta,s MOSAIQ® Oncology PACS has evolved ... image and data management solution for oncology professionals that ... information and address the requirements of the modern oncology ... System (OIS), MOSAIQ Data Director transforms the patient ...
Cached Medicine Technology:CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 2CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 3CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 4CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 5CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 6CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 7CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 8CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 9CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 10Elekta Introduces MOSAIQ Data Director, Image and Data Hub for Oncology 2Elekta Introduces MOSAIQ Data Director, Image and Data Hub for Oncology 3Elekta Introduces MOSAIQ Data Director, Image and Data Hub for Oncology 4
(Date:7/22/2014)... 2014 The market for botulinum neurotoxin ... years, owing to novel medical indications created and due ... aging societies where physical appearance is extremely valued. Although ... current competitors, new companies and technologies are setting ground ... will put the price of 1st-gen products under pressure, ...
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July ... minimally invasive procedure known as morcellation carries a risk of ... likelihood more clearly. Twenty-seven of every 10,000 women who ... of the procedure, researchers found, with the odds being highest ... a hysterectomy with morcellation use a power cutter to slice ...
(Date:7/22/2014)... Montreal, July 22, ... for a cigarette twice as often as smokers who are ... the hardest time shaking off the habit may have more ... Those insights were among the collective findings recently published in ... team of researchers based in part at Concordia University. , ...
(Date:7/22/2014)... 5i Sciences, a medical technology company focused ... Coye, M.D., M.P.H. to a role as Senior Consultant. ... the market introduction of innovative technologies that impact healthcare ... on strategies for building a successful commercial healthcare enterprise ... Coye is currently the Chief Innovation Officer of UCLA ...
(Date:7/22/2014)... Latin America Drilling fluid and Completion fluid Market Report defines ... Latin America with analysis and forecast of revenue. The drilling ... to grow from around $0.93 billion in 2013 to $1.45 ... given period. , Browse through the TOC of the Latin ... an idea of the in-depth analysis provided. This also provides ...
Breaking Medicine News(10 mins):Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 2Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 3Health News:Extra exercise helps depressed smokers kick the habit faster 2Health News:5i Sciences Announces Appointment of a Senior Healthcare Consultant and Successful Financing 2Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 6
... ... for Employees, SACRAMENTO, Calif., Sept. 8 Kurt Wetzel lost ... is seeing decreased absenteeism and lower levels of stress and,burnout among ... a,partner. And a recent study shows that employers are seeing initial ...
... WASHINGTON, Sept. 8 Parents probably,wouldn,t have guessed, ... finds middle-school students enjoy soyfoods as much as ... enjoy with tasty,and nutritious soyfoods., A plate ... took popular,menu items, including macaroni & cheese, burgers, ...
... One million Swiss Francs (around $ 885 thousand, 400 ... the amount must be destined by the winners to research ... the 2008 Balzan Prize winners were announced today in a ... Roma "La Sapienza", for the Visual Arts since 1700, Thomas ...
... patients using proton pump inhibitor (PPI) drugs. The drugs are used ... as other stomach/intestinal issues including ulcers, gastroesophageal reflux disease (GERD), dyspepsia, ... ... Denver, CO (PRWEB) September 8, 2008 -- LegalView, the number ...
... half of older patients successfully treated for colorectal cancer ... of cancer. The study, appearing in the October 15, ... of the American Cancer Society, indicates poor compliance to ... , Patients who undergo potentially curative surgery for colorectal ...
... Leaders to, Join the Smokefree Air 2010 Challenge and ... 8 College students are,falling victim to aggressive tobacco ... according to a new report released today by the,American ... of the current status of,tobacco use and policies on ...
Cached Medicine News:Health News:'Live Well for Life' Benefits Companies and Workers 2Health News:'Live Well for Life' Benefits Companies and Workers 3Health News:'Live Well for Life' Benefits Companies and Workers 4Health News:Back to School With Soy 2Health News:Balzan Foundation announced 2008 prize winners 2Health News:Balzan Foundation announced 2008 prize winners 3Health News:LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug 2Health News:LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug 3Health News:LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug 4Health News:Many colorectal cancer survivors do not receive recommended follow-up care 2Health News:Big Tobacco's Grip on Colleges and Students Loosens, But Still Holding Strong: New Report Examines Trends on Campuses 2Health News:Big Tobacco's Grip on Colleges and Students Loosens, But Still Holding Strong: New Report Examines Trends on Campuses 3Health News:Big Tobacco's Grip on Colleges and Students Loosens, But Still Holding Strong: New Report Examines Trends on Campuses 4
Double-ended. 5 mm x 7 mm tips. Designated most popular model or size....
Double-ended. Blunt and semi sharp 5 mm tips. Designated most popular model or size....
Double-ended. 6 mm x 9 mm and 6 mm x 11 mm tips....
Designated most popular model or size. 3 mm tip....
Medicine Products: